Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and associated with high response rates.
da Fonseca ARB, Justino CC, de Molla VC, Yamakawa PE, Rabelo IB, Arnold LM, Kelly RJ, Griffin M, Munir T, Hill A, Velloso EDRP, Dalessandro T, Risitano AM, Scheinberg P, Kulasekararaj AG, Arrais-Rodrigues C. da Fonseca ARB, et al. Among authors: munir t. Blood Adv. 2024 Dec 18:bloodadvances.2024014159. doi: 10.1182/bloodadvances.2024014159. Online ahead of print. Blood Adv. 2024. PMID: 39693508
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Šimkovič M, Österborg A, Laurenti L, Walker PA, Opat SS, Ciepluch H, Greil R, Hanna M, Tani M, Trněný M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, de Guibert S, Tumyan G, Laribi K, García-Marco JA, Li JY, Tian T, Liu Y, Korolkiewicz R, Szeto A, Tam CS, Jurczak W. Shadman M, et al. Among authors: munir t. J Clin Oncol. 2024 Dec 8:JCO2402265. doi: 10.1200/JCO-24-02265. Online ahead of print. J Clin Oncol. 2024. PMID: 39647999
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Sharman JP, et al. Among authors: munir t. Leukemia. 2024 Dec 3. doi: 10.1038/s41375-024-02487-1. Online ahead of print. Leukemia. 2024. PMID: 39627506 No abstract available.
Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial.
Griffin M, Gandhi S, Kelly RJ, Munir T, Trikha R, Hicks E, Jain D, Ogawa M, Yu J, Muus P, Kulasekararaj AG. Griffin M, et al. Among authors: munir t. Haematologica. 2024 Nov 28. doi: 10.3324/haematol.2024.285553. Online ahead of print. Haematologica. 2024. PMID: 39605209 Free article.
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR. Shah NN, et al. Among authors: munir t. Haematologica. 2024 Oct 3. doi: 10.3324/haematol.2024.285754. Online ahead of print. Haematologica. 2024. PMID: 39363864 Free article.
140 results